How do you determine the optimal duration for 1L doublet treatment in newly diagnosed High-Risk CLL?

I do use uMRD in the majority of patients whom I consolidate with zanu + venetoclax. I have a feeling that it is important to follow specific protocols when giving therapy so that we can effectively counsel patients on their likely outcomes.

That said, I prefer not to have to use MRD. It is not clea...

I treat patients with TP53-aberrant CLL (who are candidates for combined BTKi + BCL2i) for 2 years with uMRD4-guided stopping criteria similar to the SEQUOIA Arm D.

Among patients with high-risk CLL and indications for treatment per iwCLL criteria (Hallek et al., PMID 29540348), treatment regimens can be broadly categorized into fixed-duration, MRD-guided, and indefinite therapies. Fixed-duration doublet regimens include acalabrutinib with venetoclax per the AM...